Clinical Trial Update: Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating duvelisib after CAR-T therapy is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Duvelisib (duvelisib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Non-hodgkin Lymphoma, Acute Lymphocytic Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING